Blamoutier J
Curr Med Res Opin. 1978;5(5):366-70. doi: 10.1185/03007997809111899.
A double-blind trial was carried out in 48 patients with allergic disorders to compare the efficacy and tolerance of mequitazine and brompheniramine. Patients received either 10 mg mequitazine or 24 mg brompheniramine daily, divided into 2 doses, for 14 days. The results, analyzed from patients' answers to a questionnaire recorded on a daily basis, showed that mequitazine was at least as effective as brompheniramine and caused significantly less drowsiness throughout the trial period. Few other side-effects were reported.
对48名过敏症患者进行了一项双盲试验,以比较美喹他嗪和溴苯那敏的疗效及耐受性。患者每日服用10毫克美喹他嗪或24毫克溴苯那敏,分2次服用,共14天。根据患者对每日记录问卷的回答进行分析,结果显示,在整个试验期间,美喹他嗪的疗效至少与溴苯那敏相当,且引起的嗜睡明显较少。报告的其他副作用也很少。